AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24629554 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between MVPA-A and MVPA-SR in KIO
Number of subjects: 0
Study 22617366 — intervention group
Group type: EXPERIMENTAL
Intervention: Short nurse-based group education
Number of subjects: 0
Study 22617366 — intervention group
Group type: EXPERIMENTAL
Intervention: Long multidisciplinary group education
Number of subjects: 0
Study 20624187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) group
Number of subjects: 4
Study 20624187 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4
Study 18698064 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based group intervention (15 sessions over 5 weeks) including trauma-processing activities, cooperative play, and creative-expressive elements.
Number of subjects: 495
Study 18698064 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 495
Study 15718838 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with ALVAC‐HIV (vCP1433) and Lipo‐6T vaccines followed by subcutaneous interleukin‐2 (weeks 16, 24, 32)
Number of subjects: 71
Study 15718838 — intervention group
Group type: COMPARATOR
Intervention: Antiviral therapy alone (control)
Number of subjects: 71
Study 12795341 — intervention group
Group type: EXPERIMENTAL
Intervention: Seratrodast
Number of subjects: 16
Study 12795341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 16
Study 12795341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10695098 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg daily for 4 weeks followed by prophylaxis for 24 weeks
Number of subjects: 70
Study 10695098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 9772586 — intervention group
Group type: EXPERIMENTAL
Intervention: Shexiang Baoxinwan (SXBXW)
Number of subjects: 210
Study 9772586 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate
Number of subjects: 210
Study 8457027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestions to increase reaction to DCP and decrease reaction to DNCB
Number of subjects: 16
Study 8457027 — intervention group
Group type: COMPARATOR
Intervention: Hypnotic suggestions to decrease reaction to DCP and increase reaction to DNCB
Number of subjects: 16
Study 3026010 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin plus probenecid (1 g probenecid orally and either one vial of sodium sulbactam/ampicillin or two vials intramuscularly; each vial contained 0.5 g of sodium sulbactam and 1 g of sodium ampicillin)
Number of subjects: 45
Study 3026010 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin (two vials intramuscularly)
Number of subjects: 45
Study 31687769 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 202
Study 31687769 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 202
Study 28629269 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstacle aquatic therapy
Number of subjects: 46
Study 28629269 — intervention group
Group type: COMPARATOR
Intervention: Traditional aquatic therapy
Number of subjects: 46
Study 27054424 — intervention group
Group type: EXPERIMENTAL
Intervention: Transposed flap procedure (n=12)
Number of subjects: 24
Study 27054424 — intervention group
Group type: COMPARATOR
Intervention: Repositioned flap procedure (n=12)
Number of subjects: 24
Study 23375352 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mL 2% lidocaine infused 3 min prior to IUD insertion
Number of subjects: 40
Study 23375352 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infused 3 min prior to IUD insertion
Number of subjects: 40
Study 21417983 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular manipulation
Number of subjects: 61
Study 21417983 — intervention group
Group type: COMPARATOR
Intervention: Kocher's method
Number of subjects: 61
Study 18521540 — intervention group
Group type: EXPERIMENTAL
Intervention: AGI-1067 (300 mg daily for 12 weeks)
Number of subjects: 229
Study 18521540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 17907712 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged-based, computerized smoking cessation intervention
Number of subjects: 0
Study 17907712 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 15203800 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and nicotine gum for smoking cessation
Number of subjects: 1722
Study 11237499 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial (i.a.) cisplatinum (CDP) in three-drug regimen
Number of subjects: 221
Study 11237499 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) cisplatinum (CDP) in three-drug regimen
Number of subjects: 221
Study 11237499 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug regimen (HDMTX, ADM, IFO) with i.a. CDP
Number of subjects: 221
Study 11237499 — intervention group
Group type: COMPARATOR
Intervention: Four-drug regimen (HDMTX, ADM, IFO) with i.v. CDP
Number of subjects: 221
Study 11237499 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of limb salvage, local recurrence, and event-free survival (EFS) between i.a. and i.v. groups
Number of subjects: 221
Study 9433629 — intervention group
Group type: EXPERIMENTAL
Intervention: New statistical test for comparing mean age of onset in parents with mean age of onset in children.
Number of subjects: 0
Study 8292844 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone
Number of subjects: 42
Study 8292844 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone releasing hormone
Number of subjects: 42
Study 8292844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 2873132 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam
Number of subjects: 65
Study 2873132 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 65
Study 2873132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 28941998 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU/day
Number of subjects: 26
Study 28941998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 27322745 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4% nicotine electronic cigarettes
Number of subjects: 0
Study 27322745 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8% nicotine electronic cigarettes
Number of subjects: 0
Study 27322745 — intervention group
Group type: EXPERIMENTAL
Intervention: No nicotine electronic cigarettes
Number of subjects: 0
Study 27322745 — intervention group
Group type: COMPARATOR
Intervention: Failures and reducers (control group)
Number of subjects: 0
Study 25038542 — intervention group
Group type: EXPERIMENTAL
Intervention: Low anterior resection with ileostomy (LAR with ileostomy)
Number of subjects: 78
Study 25038542 — intervention group
Group type: COMPARATOR
Intervention: Low anterior resection without ileostomy (LAR without ileostomy)
Number of subjects: 78
Study 22112743 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of rosuvastatin (20 mg/day), ezetimibe (10 mg/day), and granulated colestimide (3.62 g/day)
Number of subjects: 17
Study 22112743 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin alone
Number of subjects: 17
Study 22112743 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of rosuvastatin, ezetimibe, and colestimide
Number of subjects: 17
Study 20531018 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOFlipid 20% (study group)
Number of subjects: 60
Study 20531018 — intervention group
Group type: COMPARATOR
Intervention: Conventional lipid emulsion (Intralipid 20%, control group)
Number of subjects: 60
Study 18262192 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g LUVs infusion
Number of subjects: 75
Study 18262192 — intervention group
Group type: EXPERIMENTAL
Intervention: 8g LUVs infusion
Number of subjects: 75
Study 18262192 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 2g and 8g LUVs infusion
Number of subjects: 75
Study 15681956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine, 0.2% administered at 5 ml/h through the IC catheter for 48 hours
Number of subjects: 36
Study 15681956 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl, 0.9%) administered at 5 ml/h through the IC catheter for 48 hours
Number of subjects: 36
Study 14597107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine treatment
Number of subjects: 0
Study 14597107 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF cell counts of 11‐20 cells/microl
Number of subjects: 0
Study 14597107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal IgM synthesis
Number of subjects: 0
Study 14597107 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF end‐titres in LATEX/IgM >/=4
Number of subjects: 0
Study 14597107 — intervention group
Group type: EXPERIMENTAL
Intervention: LATEX/T.b. gambiense positive CSF
Number of subjects: 0
Study 10550734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg once daily
Number of subjects: 821
Study 10550734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 180 mg once daily
Number of subjects: 821
Study 10550734 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg once daily (active control)
Number of subjects: 821
Study 10550734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study 10550734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 821
Study 10550734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 821
Study 8810686 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with cyclosporin (CyA) and methotrexate, mean final dose of 2.97 mg/kg per day CyA
Number of subjects: 0
Study 8810686 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 0
Study 1921733 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg micronized 17 beta-oestradiol (E2) + 50 mg micronized progesterone
Number of subjects: 30
Study 1921733 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg micronized 17 beta-oestradiol (E2) + 100 mg micronized progesterone
Number of subjects: 30
Study 1921733 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg micronized 17 beta-oestradiol (E2) + 200 mg micronized progesterone
Number of subjects: 30
Study 1921733 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg micronized 17 beta-oestradiol (E2) + micronized progesterone (various doses)
Number of subjects: 30
Study 1921733 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study 7048451 — intervention group
Group type: EXPERIMENTAL
Intervention: yohimbine chlorhydrate (4 mg)
Number of subjects: 9
Study 7048451 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol (40 mg)
Number of subjects: 9
Study 7048451 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 30727991 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention
Number of subjects: 0
Study 30727991 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention (information flyer as standard of care)
Number of subjects: 0
Study 30727991 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 28264176 — intervention group
Group type: EXPERIMENTAL
Intervention: VoiceDiab application
Number of subjects: 54
Study 25892647 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150mg once daily
Number of subjects: 1218
Study 25892647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1218
Study 24315409 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (two interactive workshops)
Number of subjects: 216
Study 24315409 — intervention group
Group type: COMPARATOR
Intervention: Control group (information sent by surface mail)
Number of subjects: 216
Study 22855064 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 18775045 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal temperature monitoring (ETM) during pulmonary vein isolation
Number of subjects: 359
Study 18775045 — intervention group
Group type: COMPARATOR
Intervention: Non-esophageal temperature monitoring (non-ETM) during pulmonary vein isolation
Number of subjects: 359
Study 18775045 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ETM and non-ETM groups
Number of subjects: 359
Study 17456173 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing workload instrument
Number of subjects: 48
Study 15823766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 600 mg once daily for 10 days
Number of subjects: 271
Study 15823766 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg once daily for 10 days
Number of subjects: 271
Study 15823766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 271
Study 15823766 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 271
Study 12177080 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (evidence based educational outreach visit)
Number of subjects: 158
Study 12177080 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group (non-structured educational session)
Number of subjects: 158
Study 12177080 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 158
Study 9585747 — intervention group
Group type: EXPERIMENTAL
Intervention: $10 monetary incentive
Number of subjects: 1004
Study 9585747 — intervention group
Group type: EXPERIMENTAL
Intervention: $5 monetary incentive
Number of subjects: 1004
Study 9585747 — intervention group
Group type: COMPARATOR
Intervention: No monetary incentive
Number of subjects: 1004
Study 9585747 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (brief motivational education session)
Number of subjects: 1004
Study 9585747 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of TB infection
Number of subjects: 1004
Study 7698317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu(II)(aq.) added to isolated samples of RA SF ultrafiltrates
Number of subjects: 7
Study 7698317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu(II) treated samples of intact SF
Number of subjects: 7
Study 7698317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu(II) ions in inflammatory SF
Number of subjects: 7
Study 2692973 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol (0.5 mg tablet in the morning, placebo at night)
Number of subjects: 51
Study 2692973 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release amitriptyline (25 mg capsule at night, placebo in the morning)
Number of subjects: 51
Study 856371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive individual anti-smoking advice
Number of subjects: 0
Study 856371 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30782000 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide (TH) 40 mg
Number of subjects: 105
Study 30782000 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) 100 IU
Number of subjects: 105
Study 30782000 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (SS) 0.9%
Number of subjects: 105
Study 29049653 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 2.5 mg
Number of subjects: 632
Study 29049653 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 5 mg
Number of subjects: 632
Study 29049653 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 10 mg
Number of subjects: 632
Study 29049653 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 20 mg
Number of subjects: 632
Study 29049653 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 40 mg (4-week dose escalation)
Number of subjects: 632
Study 29049653 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous semaglutide 1.0 mg
Number of subjects: 632
Study 29049653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 632
Study 26056177 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-Dexamethasone (VD)
Number of subjects: 502
Study 26056177 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-Thalidomide-Dexamethasone (VTD)
Number of subjects: 502
Study 26056177 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-Melphalan-Prednisone (VMP)
Number of subjects: 502
Study 23474578 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde
Number of subjects: 54
Study 23474578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulphate
Number of subjects: 54
Study 23474578 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol
Number of subjects: 54
Study 21147421 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Number of subjects: 31
Study 18447101 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of bupropion, nicotine patch, and individual counseling for 8 weeks
Number of subjects: 559
Study 16528136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-80 mg b.i.d.)
Number of subjects: 123
Study 16528136 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride (50-100 mg b.i.d.)
Number of subjects: 123
Study 16528136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 123
Study 16528136 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride
Number of subjects: 123
Study 12972678 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (after giving a videotaped speech)
Number of subjects: 25
Study 12972678 — intervention group
Group type: COMPARATOR
Intervention: Control condition (after reading children's magazines)
Number of subjects: 25
Study 12972678 — intervention group
Group type: EXPERIMENTAL
Intervention: Low heart-rate reactivity group
Number of subjects: 25
Study 11012492 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar block with 10 ml of 0.25% bupivacaine
Number of subjects: 60
Study 11012492 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine 150 microg.kg‐1
Number of subjects: 60
Study 8934062 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ultrasound evaluation
Number of subjects: 235
Study 8934062 — intervention group
Group type: COMPARATOR
Intervention: No ultrasound evaluation (Control)
Number of subjects: 235
Study 1329742 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g orally b.i.d.)
Number of subjects: 14
Study 1329742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10269519 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group with feedback on individual performance
Number of subjects: 0
Study 10269519 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group without feedback
Number of subjects: 0
Study 10269519 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual with feedback
Number of subjects: 0
Study 31761958 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical rapamycin
Number of subjects: 36
Study 31761958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29641348 — intervention group
Group type: EXPERIMENTAL
Intervention: Translumbar laparoendoscopic single‐site donor nephrectomy (LESS‐DN)
Number of subjects: 50
Study 29641348 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic donor nephrectomy (LDN)
Number of subjects: 50
Study 27798035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-based dietary intervention supplemented with extra virgin olive oil and mixed nuts until delivery.
Number of subjects: 1230
Study 27798035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-based dietary intervention
Number of subjects: 1230
Study 25243546 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior retroperitoneoscopic adrenalectomy (PRA)
Number of subjects: 65
Study 25243546 — intervention group
Group type: COMPARATOR
Intervention: Lateral transperitoneal laparoscopic adrenalectomy (LTLA)
Number of subjects: 65
Study 22385499 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training sessions with video-based feedback (Feedback group)
Number of subjects: 22
Study 22385499 — intervention group
Group type: COMPARATOR
Intervention: Driving refresher course without driving-specific feedback (Control group)
Number of subjects: 22
Study 19377716 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cancer screening by visual inspection (3 rounds between 1996 and 2004)
Number of subjects: 13
Study 19377716 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 13
Study 19377716 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cancer screening by visual inspection
Number of subjects: 13
Study 17576782 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-daily hydrocortisone dosing (mean total daily dose: 8.3 +/- 2.6 mg/m2)
Number of subjects: 20
Study 17576782 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily hydrocortisone dosing (mean total daily dose: 7.6 +/- 2.1 mg/m2)
Number of subjects: 20
Study 17576782 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning doses > 4 mg/m2
Number of subjects: 20
Study 17576782 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening doses > 2.5 mg/m2
Number of subjects: 20
Study 17576782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive testing (34 paired tests)
Number of subjects: 20
Study 15120772 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied morphine sulfate 10 mg in Intrasite gel
Number of subjects: 6
Study 15120772 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneously administered morphine sulfate 10 mg
Number of subjects: 6
Study 11460523 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 19
Study 11460523 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 19
Study 9513329 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and small dose of fentanyl (Group P)
Number of subjects: 33
Study 9513329 — intervention group
Group type: COMPARATOR
Intervention: Thiopental and sevoflurane (Group S)
Number of subjects: 33
Study 7800156 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drinks
Number of subjects: 0